ProPublica, which is run by Paul Steiger, the former chairman of the Wall Street Journal, and was founded purely as an investigative news outlet, today reports:
“The Food and Drug Administration left medicines on the market for years after discovering they were approved based on fraudulent studies by Cetero Research, which did testing for drug companies worldwide. Turns out that wasn’t an anomaly: The agency’s slow, secretive response in the Cetero case mirrors how it handled an earlier instance of scientific misconduct at another contract research organization, MDS Pharma Services.”
Most interesting is that, among the drugs whose FDA approval hinged on research by Cetero, was Temodar IV.
And Temodar IV is manufactured by (you guessed it) Merck & Co: